Global Urological Cancer Market to 2022 - Strong Growth Driven by Rising Prevalence, Increased Uptake of Hormone Therapies and Approval of Novel Biologics

  • ID: 3784840
  • Report
  • Region: Global
  • 143 Pages
  • GBI Research
1 of 6
Global Urological Cancers Market Will Double to $35.9 billion by 2022

FEATURED COMPANIES

  • AstraZeneca
  • Bavarian Nordic
  • EUSA Pharma
  • Johnson & Johnson
  • Merck KGaA
  • Roche
  • MORE
Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered in this report – accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.

A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies – such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope

- Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
- The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market?
- What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications?
- How will the market shares and CAGRs of the top 20 companies compare within this therapy area?
- What proportion of the key players’ revenues will be attributable to urological cancers?

Reasons to buy

This report will allow you to -
- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
- Visualize the composition of the urological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
- Analyze the urological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
- Understand the growth in patient epidemiology and market revenues for the urological cancer market globally and across the key players and product types
- Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various urological cancers
- Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AstraZeneca
  • Bavarian Nordic
  • EUSA Pharma
  • Johnson & Johnson
  • Merck KGaA
  • Roche
  • MORE
1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Cluster Introduction
2.2 Symptoms
2.3 Etiology and Pathophysiology
2.3.1 Etiology
2.3.2 Pathophysiology
2.4 Co-morbidities and Complications
2.5 Epidemiology Patterns; Prevalence, Patient Segmentation, and Diagnostic and Treatment Usage Rates
2.5.1 Bladder Cancer
2.5.2 Kidney Cancer
2.5.3 Prostate Cancer
2.5.4 Testicular Cancer
2.6 Treatment
2.6.1 Chemotherapy
2.6.2 Surgery and Radiation Therapy
2.6.3 Hormonal Therapies
2.6.4 Targeted Therapies

3 Key Marketed Products
3.1 Overview
3.2 Zytiga (abiraterone acetate)
3.3 Xtandi (enzalutamide)
3.4 Sutent (sunitinib malate)
3.5 Votrient (pazopanib hydrochloride)
3.6 Inlyta (axitinib)
3.7 Jevtana (cabazitaxel)
3.8 Xofigo (radium Ra 223 dichloride)
3.9 Provenge (sipuleucel-T)
3.10 Opdivo (nivolumab) - Bristol-Myers Squibb
3.11 Conclusion

4 Pipeline Landscape Assessment
4.1 Overview
4.2 Pipeline Development Landscape
4.3 Molecular Targets in the Pipeline
4.4 Clinical Trials
4.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.4.4 Aggregate Clinical Program Size by Stage of Development, Indication, Molecule Type and Molecular Target
4.5 Conclusion
4.6 Assessment of Key Pipeline Products
4.6.1 Atezolizumab - Roche
4.6.2 Durvalumab - AstraZeneca
4.6.3 Durvalumab + Tremelimumab - MedImmune
4.6.4 Apalutamide - Johnson & Johnson
4.6.5 Avelumab - Merck KGaA
4.6.6 Tivozanib - EUSA Pharma
4.6.7 Eoquin - Spectrum Pharmaceuticals
4.6.8 Prostvac - Bavarian Nordic
4.7 Conclusion

5 Multi-Scenario Market Forecast to 2022
5.1 Overall Market Size
5.2 Generic Penetration
5.3 Revenue Forecast by Molecular Target
5.3.1 Androgen Receptor Antagonists
5.3.2 Programmed Cell Death Protein 1 Inhibitor
5.3.3 VEGF Inhibitors
5.3.4 GnRH Inhibitors
5.3.5 Tubulin Inhibitors
5.3.6 CTLA-4 Inhibitors

6 Company Analysis and Positioning
6.1 Revenue and Market Share Analysis by Company
6.1.1 Pfizer - Will a Patent Cliff Be Avoided Following the Expiries of Sutent and Inlyta?
6.1.2 Novartis - How Will Upcoming Patent Expiries Affect Urological Cancer Revenues?
6.1.3 Johnson & Johnson - How Will Zytiga Perform in an Increasingly Competitive Prostate Cancer Treatment Market?
6.1.4 Astellas - What Will Become of Xtandi?
6.1.5 AstraZeneca - Will Sales Revenues Increase over the Forecast Period?
6.1.6 Bristol-Myers Squibb - How Will Cancer Immunotherapies Affect Urological Cancers?
6.2 Company Landscape
6.3 Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region, Year and Value
7.1.2 Deals by Stage of Development and Value
7.1.3 Deals by Molecule Type, Molecular Target and Value
7.1.4 Table for Licensing Deals Valued Above $100m
7.2 Co-development Deals
7.2.1 Deals by Region, Year and Value
7.2.2 Deals by Stage of Development and Value
7.2.3 Deals by Molecule Type, Molecular Target and Value

8 Appendix
8.1 References
8.2 Table of All Clinical Stage Pipeline Products
8.3 Abbreviations
8.4 Methodology
8.4.1 Coverage
8.4.2 Secondary Research
8.4.3 Market Size and Revenue Forecasts
8.4.4 Pipeline Analysis
8.4.5 Competitive Landscape
8.5 Contact Us
8.6 Disclaimer

1.1 List of Tables
Table 1: Urologic Oncology, Global, Symptoms of the Most Prevalent Urological Cancers, 2016
Table 2: Urologic Oncology, Global, Complications Associated with Bladder, Kidney, Prostate and Testicular Cancers
Table 3: Urologic Oncology, Global, Epidemiology of The Most Prevalent Urological Cancers, 2015
Table 4: Urologic Oncology, Optimal and Actual Chemotherapy Usage Rates Across All Cancer Stages, 2010
Table 5: Urologic Oncology, Global, Reconstructive Surgery following Bladder Cancer Resection, 2016
Table 6: Urologic Oncology, Optimal and Actual Radiation Therapy Usage Rates in US, 1995-2000
Table 7: Urologic Oncology Therapeutics Market, Global, Approved Indications for Zytiga, 2016
Table 8: Urologic Oncology Therapeutics Market, Global, Approved Indications for Xtandi, 2016
Table 9: Urologic Oncology Therapeutics Market, Global, Approved Indications for Sutent, 2016
Table 10: Urologic Oncology Therapeutics Market, Global, Approved Indications for Votrient, 2016
Table 11: Urologic Oncology Therapeutics Market, Global, Approved Indications for Inlyta, 2016
Table 12: Urologic Oncology Therapeutics Market, Global, Approved Indications for Jevtana, 2016
Table 13: Urologic Oncology Therapeutics Market, Global, Approved Indications for Xofigo, 2016
Table 14: Urologic Oncology Therapeutics Market, Global, Approved Indications for Provenge, 2016
Table 15: Urologic Oncology Therapeutics Market, Global, Approved Indications for Opdivo, 2016
Table 16: Urologic Oncology, Global, Usage of Generics Across Key Indications, 2016
Table 17: Urologic Oncology, Global, Licensing Deals Valued Above $100m, 2006-2016
Table 18: Urologic Oncology, Global, Co-development Deals Valued Above $100m, 2006-2016
Table 19: Oncology, Global, All Clinical Trial Stage Pipeline Products, 2016
Table 20: Abbreviations

1.2 List of Figures
Figure 1: Urologic Oncology, Major Markets, Treatment Usage Patterns for Bladder Cancer, Patients (’000), 2015-2022
Figure 2: Urologic Oncology, Major Markets, Treatment Usage Patterns for Kidney Cancer, Patients (’000), 2015-2022
Figure 3: Urologic Oncology, Major Markets, Treatment Usage Patterns for Prostate Cancer, Patients (’000), 2015-2022
Figure 4: Urologic Oncology, Major Markets, Treatment Usage Patterns for Testicular Cancer, Patients (’000), 2015-2022
Figure 5: Urological Cancer, Global, Key Marketed Products and Approved Indications, 2015
Figure 6: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Zytiga ($bn), 2011-2022
Figure 7: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Xtandi ($bn), 2012-2022
Figure 8: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Sutent ($bn), 2006-2022
Figure 9: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Votrient ($bn), 2010-2022
Figure 10: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Inlyta ($m), 2012-2022
Figure 11: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Jevtana ($m), 2012-2022
Figure 12: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Xofigo ($bn), 2013-2022
Figure 13: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Provenge ($m), 2010-2022
Figure 14: Urologic Oncology Therapeutics Market, Global, Annual Revenues for Opdivo ($bn), 2015-2022
Figure 15: Urologic Oncology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016
Figure 16: Urologic Oncology Therapeutics Market, Global, Pipeline for Oncology by Stage of Development, Molecule Type and Program Type, 2016
Figure 17: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Stage of Development, 2016
Figure 18: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecule Type, 2016
Figure 19: Urologic Oncology Therapeutics Market, Global, Pipeline for Oncology by Molecular Target, 2016
Figure 20: Urologic Oncology Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016
Figure 21: Urologic Oncology Therapeutics Market, Global, Pipeline for Key Oncology Indications by Molecular Target, 2016
Figure 22: Urologic Oncology Therapeutics Market, Global, Urologic Clinical Trial by Indication (%), 2006-2016
Figure 23: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006-2016
Figure 24: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006-2016
Figure 25: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016
Figure 26: Urologic Oncology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016
Figure 27: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (months), 2006-2016
Figure 28: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006-2016
Figure 29: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006-2016
Figure 30: Urologic Oncology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006-2016
Figure 31: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (participants), 2006-2016
Figure 32: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006-2016
Figure 33: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 34: Urologic Oncology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 35: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006-2016
Figure 36: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006-2016
Figure 37: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006-2016
Figure 38: Urologic Oncology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006-2016
Figure 39: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for atezolizumab ($bn), 2016-2022
Figure 40: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Durvalumab ($bn), 2017-2022
Figure 41: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Durvalumab + Tremelimumab ($m), 2018-2022
Figure 42: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Apalutamide ($m), 2018-2022
Figure 43: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Avelumab ($m), 2016-2022
Figure 44: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Tivozanib ($m), 2016-2022
Figure 45: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Eoquin ($m), 2017-2022
Figure 46: Urologic Oncology Therapeutics Market, Global, Revenue Forecast for Prostvac ($m), 2016-2022
Figure 47: Urologic Oncology, Global, Market Size ($bn), 2015-2022
Figure 48: Urologic Oncology, Global, Market Size ($bn), 2015-2022
Figure 49: Urologic Oncology, Global, Annual Revenue Forecast for Key Products ($bn), 2015-2022
Figure 50: Urologic Oncology, Global, Annual Revenue Forecast for Androgen Receptor ($bn), 2015-2022
Figure 51: Urologic Oncology, Global, Annual Revenue Forecast for Programmed Cell Death Protein 1 Inhibitor ($bn), 2015-2022
Figure 52: Urologic Oncology, Global, Annual Revenue Forecast for VEGF Inhibitors ($bn), 2015-2022
Figure 53: Urologic Oncology, Global, Annual Revenue Forecast for GNRH Inhibitors ($m), 2015-2022
Figure 54: Urologic Oncology, Global, Annual Revenue Forecast for Tubulin Inhibitors ($m), 2015-2022
Figure 55: Urologic Oncology, Global, Annual Revenue Forecast for CTLA-4 ($m), 2017-2022
Figure 56: Urologic Oncology, Global, Companies by Type, Cluster by Growth and Market Share, 2015-2022
Figure 57: Urologic Oncology Therapeutics Market, Global, Forecast Revenues by Company, 2015-2022
Figure 58: Urologic Oncology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015-2022
Figure 59: Urologic Oncology, Global, Companies by Compound Annual Growth Rate (%), 2015-2022
Figure 60: Urologic Oncology, Global, Revenues by Product Type, 2015-2022
Figure 61: Urologic Oncology, Global, Pfizer Urologic Oncology Annual Revenue Forecast ($bn), 2015-2022
Figure 62: Urologic Oncology, Global, Novartis AG Annual Revenue Forecast ($bn), 2015-2022
Figure 63: Urologic Oncology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015-2022
Figure 64: Urologic Oncology, Global, Astellas Pharma Inc. Annual Revenue Forecast ($bn), 2015-2022
Figure 65: Urologic Oncology, AstraZeneca Plc. Annual Revenue Forecast ($bn), 2015-2022
Figure 66: Urologic Oncology, Bristol-Myers Squibb Annual Revenue Forecast ($bn), 2015-2022
Figure 67: Urologic Oncology, Global, Companies by Type, 2015-2022
Figure 68: Urologic Oncology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Urological Cancer Specialization, 2015-2022
Figure 69: Urologic Oncology, Global, Proportion of Total Company Revenue Attributed to Urological Cancer, 2015-2022
Figure 70: Urologic Oncology, Global, Proportion of Total Company Revenue Attributed to Urological Cancers, Top Six Companies ($bn), 2015-2022
Figure 71: Urologic Oncology, Global, Licensing Deals, 2006-2016
Figure 72: Urologic Oncology, Global, Licensing Deals by Indication and Value, 2006-2016
Figure 73: Urologic Oncology, Global, Licensing Deals, 2006-2016
Figure 74: Urologic Oncology, Global, Licensing Deals by Molecule Type and Molecular Target, 2006-2016
Figure 75: Urologic Oncology, Global, Co-development Deals, 2006-2016
Figure 76: Urologic Oncology, Global, Co-development Deals by Indication and Value, 2006-2016
Figure 77: Urologic Oncology, Global, Co-development Deals, 2006-2016
Figure 78: Urologic Oncology, Global, Co-development Deals by Molecule Type and Molecular Target, 2006-2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AstraZeneca
  • Bavarian Nordic
  • EUSA Pharma
  • Johnson & Johnson
  • Merck KGaA
  • Roche
  • MORE
The urological cancers market, including bladder, kidney, prostate and testicular cancer, will increase from $17.9 billion in 2015 to $35.9 billion by 2022, at a substantial compound annual growth rate of 10.39%, according to the publisher.

Their latest report states that this strong market growth will be driven by the predicted emergence of targeted therapies for bladder cancer and increasing prostate and kidney cancer prevalence.

One of the publishers analyst's explains: “The development and approval of immune checkpoint inhibitors will lower the associated toxicity of urological cancer therapies and increase their usage in typically poor-performance patients, who have a reduced functional status. Targeted treatment administration will increase patients’ overall survival and enable more rounds of chemotherapy to be given.

“It is predicted that two new urological cancer drugs for the treatment of bladder cancer – Roche’s atezolizumab and AstraZeneca’s durvalumab – will achieve blockbuster status by 2022. The former is anticipated to achieve revenue of $2.5 billion in 2022, following approval from late 2016, and its uptake will be driven by a lack of targeted therapies for bladder cancer, along with increasing prevalence and clinician familiarity.

“The latter is anticipated to generate $1.2 billion in 2022, following its expected approval in 2017. It is expected to be one of an increasing number of cancer immunotherapies for bladder cancer, providing less toxic options for treatment of the malignancy, and enabling administration to patients with poorer performance statuses.”

Although drugs such as atezolizumab and durvalumab are not expected to surpass the revenues generated by the currently marketed drugs Opdivo or Xtandi due to a competitive market landscape, their approval and uptake will cause shifts in market dynamics.

This report provides analysis of the global urological cancer space across the seven major countries of the US, France, Germany, Italy, Spain, the UK, and Japan. It includes annualized market data from 2015 and forecast to 2022.
Note: Product cover images may vary from those shown
5 of 6
- AstraZeneca
- Bavarian Nordic
- EUSA Pharma
- Johnson & Johnson
- Merck KGaA
- Roche
- Spectrum Pharmaceuticals
- Tremelimumab - MedImmune
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll